ReNeuron Group plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ReNeuron Group plc
Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.
Korea Health Industry Development Institute President Soon-Do Cha talks to Scrip how the government agency’s support strategy to the domestic biopharma industry may be changing in line with the industry’s increased globalization move and how he views the country’s policy stance should improve going forward to meet its goal of becoming a strong biohealth nation.
The National Health Service in England says it will be the first health system in the world to roll out a subcutaneously administered formulation of Tecentriq, after the UK MHRA became the first drug regulator to approve the product.
Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.